建模降低美国阿片类药物相关发病率与死亡率的干预策略
该研究采用决策分析动态马尔可夫模型,基于2010-2018年多项美国全国调查数据校准,预测2020-2029年阿片类药物过量致死负担及干预效果。结果提示积极部署循证干预可减少至少三分之一死亡,但对OUD患病数影响有限。
要点
- 治疗扩展(假设年 uptake 增加35%持续4年、复发减少50%)单独降低死亡25.3%。
- 纳洛酮分发(假设降低病死率5%)单独降低死亡15.4%。
- 处方减少(每年5%)单独仅降低死亡0.3%。
适用人群与场景
- 美国一般人群中12岁及以上个体,包括处方阿片类医疗使用、非医疗使用、海洛因使用、处方/海洛因/联合阿片使用障碍(OUD)、7类治疗之一或非致死/致死过量者。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 模型模拟的干预包括:处方减少(每年5%)、纳洛酮分发(假设降低病死率5%)、治疗扩展(假设年 uptake 增加35%持续4年、复发减少50%),每种干预与现状比较。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 决策分析动态马尔可夫模型,基于2010-2018年National Survey on Drug Use and Health、CDC、NHANES、美国人口普查、NESARC-III数据校准,预测2020-2029年。
- 模型对未来致死和非致死过量率假设最敏感。
证据类型、等级与局限
- 研究类型:决策分析动态马尔可夫模型(模拟研究),非RCT或观察性研究。
- 局限:结果基于模型假设和校准数据,对未来致死/非致死过量率假设敏感;干预效果为模型估计值,需前瞻性验证。
对床旁实践的改变
- 模型提示联合部署处方减少、纳洛酮分发和治疗扩展可能大幅减少阿片过量死亡,但单独处方减少效果甚微。
- 对OUD患病数影响有限,提示需持续治疗和预防策略。
- 模型预测值不能直接作为临床决策阈值,需结合本地数据和前瞻性验证。
指南或共识出处
- 原文未提及
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: The US opioid epidemic is complex and dynamic, yet relatively little is known regarding its likely future impact and the potential mitigating impact of interventions to address it.
OBJECTIVE: To estimate the future burden of the opioid epidemic and the potential of interventions to address the burden.
DESIGN, SETTING, AND PARTICIPANTS: A decision analytic dynamic Markov model was calibrated using 2010-2018 data from the National Survey on Drug Use and Health, Centers for Disease Control and Prevention, National Health and Nutrition Examination Survey, the US Census, and National Epidemiologic Survey on Alcohol and Related Conditions-III. Data on individuals 12 years or older from the US general population or with prescription opioid medical use; prescription opioid nonmedical use; heroin use; prescription, heroin, or combined prescription and heroin opioid use disorder (OUD); 1 of 7 treatment categories; or nonfatal or fatal overdose were examined. The model was designed to project fatal opioid overdoses between 2020 and 2029.
EXPOSURES: The model projected prescribing reductions (5% annually), naloxone distribution (assumed 5% reduction in case-fatality), and treatment expansion (assumed 35% increase in uptake annually for 4 years and 50% relapse reduction), with each compared vs status quo.
MAIN OUTCOMES AND MEASURES: Projected 10-year overdose deaths and prevalence of OUD.
RESULTS: Under status quo, 484 429 (95% confidence band, 390 543-576 631) individuals were projected to experience fatal opioid overdose between 2020 and 2029. Projected decreases in deaths were 0.3% with prescribing reductions, 15.4% with naloxone distribution, and 25.3% with treatment expansion; when combined, these interventions were associated with 179 151 fewer overdose deaths (37.0%) over 10 years. Interventions had a smaller association with the prevalence of OUD; for example, the combined intervention was estimated to reduce OUD prevalence by 27.5%, from 2.47 million in 2019 to 1.79 million in 2029. Model projections were most sensitive to assumptions regarding future rates of fatal and nonfatal overdose.
CONCLUSIONS AND RELEVANCE: The findings of this study suggest that the opioid epidemic is likely to continue to cause tens of thousands of deaths annually over the next decade. Aggressive deployment of evidence-based interventions may reduce deaths by at least a third but will likely have less impact for the number of people with OUD.
参考来源
- Ballreich J, Mansour O, Hu E, et al. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US. JAMA Netw Open. 2020. PMID: 33146732. doi:10.1001/jamanetworkopen.2020.23677
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。